- The Lancet commission redefines obesity diagnosis, moving beyond BMI to include fat levels and organ function assessments.
- A new "Preclinical Obesity" category identifies excess body fat without illness, aiming for precise diagnoses and better healthcare outcomes.
The Lancet Diabetes & Endocrinology Commission has introduced a new approach to diagnosing obesity, moving beyond the widely used Body Mass Index (BMI) as a sole determinant. Published on January 14, the commission’s findings aim to address the limitations of BMI in assessing obesity accurately.
BMI, a weight-to-height ratio, has long been the global standard for diagnosing obesity. Current thresholds classify individuals with a BMI under 18.5 as underweight, 18.5–24.9 as normal, 25–29.9 as overweight, and over 30 as obese. However, experts argue this method can lead to misdiagnosis. Individuals with excess body fat might not exceed a BMI of 30 but could still face obesity-related health risks. Conversely, those with high muscle mass may have a BMI over 30 without needing medical intervention.
The commission proposes a more nuanced definition, introducing a new category called "Preclinical Obesity." This classification identifies individuals with excess body fat but no associated illness. Diagnosis would involve measuring fat levels and assessing organ function rather than relying solely on BMI.
According to the commission, preclinical obesity is not an illness but a physical characteristic, potentially an early stage of clinical obesity or a benign condition.
The initiative has garnered support from global organizations such as the American Heart Association, the Chinese Diabetes Society, and the World Obesity Federation. Experts from the World Health Organization also contributed to the commission, which began its work in 2019.
While the commission's recommendations do not focus on treatments like GLP-1 drugs, such as those developed by Eli Lilly and Novo Nordisk, they emphasize that clearer diagnostic criteria could guide their appropriate use. The proposed changes could also influence health insurance policies, encouraging coverage for obesity treatments as a standalone condition rather than requiring related illnesses like diabetes.
With over one billion people worldwide estimated to have obesity, the commission’s goal is to refine diagnosis, improve healthcare resource allocation, and address debates within the medical community over whether obesity should be classified as a disease. The long-term impact of these changes on global obesity diagnosis remains uncertain.
Edited by Harshajit Sarmah
